May. 28 at 11:55 AM
$CRBP Started small position to play obesity data.
Thesis is simple. If 913 gets 4%+ weight loss at 12 weeks with acceptable AE profile, potential upside is enormous. If it fails, downside *should* be limited from here given
$7/share cash position and 701 having a viable registrational path.
Won't be surprised of it falls more than would be expected initially based on cash/701 but I'd expect it to eventually rebound, especially with pembro combo data around the corner (which should be very good).
